Breaking Now: Biden's Disturbing Plan to "Reset" America
The “Great Reset” started on January 20th with the inauguration of Joe Biden. Between now and the midterms, the American economy could be reshaped forever – and renowned analyst Jeff Brown has found the “lynchpin” to the entire plan.

NASDAQ:SBTX - Silverback Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.25
  • Forecasted Upside: 33.50 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$37.64
▼ -1.3 (-3.34%)
1 month | 3 months | 12 months
Get New Silverback Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$50.25
▲ +33.50% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Silverback Therapeutics in the last 3 months. The average price target is $50.25, with a high forecast of $60.00 and a low forecast of $44.00. The average price target represents a 33.50% upside from the last price of $37.64.
Breaking Now: Biden's Disturbing Plan to "Reset" America
The “Great Reset” started on January 20th with the inauguration of Joe Biden. Between now and the midterms, the American economy could be reshaped forever – and renowned analyst Jeff Brown has found the “lynchpin” to the entire plan.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Silverback Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2021SVB LeerinkBoost Price TargetOutperform$40.00 ➝ $49.00High
i
Rating by D. Graybosch at SVB Leerink LLC
4/6/2021SVB LeerinkBoost Price TargetOutperform$40.00 ➝ $49.00High
i
Rating by D. Graybosch at SVB Leerink LLC
3/30/2021Stifel NicolausBoost Price TargetBuy$58.00 ➝ $60.00High
i
3/30/2021The Goldman Sachs GroupBoost Price TargetBuy$43.00 ➝ $48.00High
i
12/29/2020SVB LeerinkInitiated CoverageOutperform$40.00N/A
i
Rating by D. Graybosch at SVB Leerink LLC
12/29/2020Stifel NicolausInitiated CoverageBuy$58.00N/A
i
12/29/2020HC WainwrightInitiated CoverageBuy$44.00N/A
i
Rating by E. White at HC Wainwright
12/29/2020The Goldman Sachs GroupInitiated CoverageBuy$43.00N/A
i
(Data available from 4/17/2016 forward)
Silverback Therapeutics logo
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $37.64
$36.58
$39.36

50 Day Range

MA: $47.27
$34.08
$60.41

52 Week Range

Now: $37.64
$24.22
$63.41

Volume

131,993 shs

Average Volume

236,660 shs

Market Capitalization

$1.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Silverback Therapeutics?

The following equities research analysts have issued reports on Silverback Therapeutics in the last year: HC Wainwright, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for SBTX.

What is the current price target for Silverback Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Silverback Therapeutics in the last year. Their average twelve-month price target is $50.25, suggesting a possible upside of 33.5%. Stifel Nicolaus has the highest price target set, predicting SBTX will reach $60.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $44.00 for Silverback Therapeutics in the next year.
View the latest price targets for SBTX.

What is the current consensus analyst rating for Silverback Therapeutics?

Silverback Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SBTX will outperform the market and that investors should add to their positions of Silverback Therapeutics.
View the latest ratings for SBTX.

What other companies compete with Silverback Therapeutics?

Other companies that are similar to Silverback Therapeutics include Sana Biotechnology, Abcam, Cronos Group, Genus, Abcam, BTG, Seer, MorphoSys, Nuvation Bio, ImmunityBio, Immunocore, BioAtla, Cullinan Oncology, Kinnate Biopharma and Cricut.

How do I contact Silverback Therapeutics' investor relations team?

The company's listed phone number is 206-456-2900. The official website for Silverback Therapeutics is www.silverbacktx.com.

Breaking Now: Biden's Disturbing Plan to "Reset" America
The “Great Reset” started on January 20th with the inauguration of Joe Biden. Between now and the midterms, the American economy could be reshaped forever – and renowned analyst Jeff Brown has found the “lynchpin” to the entire plan.